Bedaquiline: A Breakthrough in Tuberculosis Treatment

Abstract

Tuberculosis (TB) remains a leading cause of death from a single infectious agent, with its global control severely undermined by the proliferation of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. For decades, the therapeutic landscape for these formidableformsof TB wasdefinedbyarchaic,prolonged,andhighly toxic treatmentregimens, which yielded cure rates of only 50–60%. The accelerated approval of bedaquiline in 2012, the first new anti-TB drug from a novel class in over 40 years, heralded a paradigm shift in the management of drug-resistant TB. Bedaquiline introduced a unique mechanism of action, the specific inhibition of the proton pump of mycobacterial ATP synthase, a critical enzyme in the bacterium\'s energy metabolism. This novel target confers potent bactericidal and sterilizing activity against both actively replicating and dormant, non-replicating bacilli, and crucially, exhibits no cross-resistance with existing anti-TB drug classes.Pivotal Phase II clinical trials (C208 and C209) provided the foundational evidence for its efficacy, demonstrating that the addition of bedaquiline to a background regimen significantly accelerated the time to sputum culture conversion and substantially improved final treatment success rates, even in patients with pre-XDR and XDR-TB. Its introduction has served as the cornerstone fora revolution in treatment strategy, enabling the development of all-oral, shorter- course regimens. Groundbreaking trials such as Nix-TB, ZeNix, and TB-PRACTECAL have validated 6-month, bedaquiline-based regimen that achieve cure rates approaching 90%, while being significantly safer and more tolerable than the older, injectable- based standards of care. While significant challenges related to its safety profile (notably QTc interval prolongation), the inevitable emergence of drug resistance, and the persistent struggle for equitable global access remain, bedaquiline has fundamentally transformed the prognosis for patients with drug-resistant TB. It has converted a debilitating, often fatal disease into a manageableand highlycurable conditionforthevastmajorityofpatients.Thisarticle providesa comprehensive review of the discovery, detailed pharmacology, clinical evidence, and the profound, paradigm-shifting impact of bedaquiline on the global fight against tuberculosis.

Introduction

1. The Crisis of Drug-Resistant Tuberculosis

Tuberculosis remains a major global health threat, made worse by the rise of drug-resistant forms such as MDR-TB, pre-XDR-TB, and XDR-TB. Resistance develops due to poor treatment, weak health systems, and the spread of already-resistant strains. Without universal drug susceptibility testing, standard treatments can worsen resistance.

2. Pre-Bedaquiline Era: Ineffective and Toxic Treatment

Before 2012, MDR-TB therapy was long (18–24 months), painful, toxic, and only about 50–60% effective. Injectables like amikacin caused permanent hearing loss and kidney damage. New medicines were urgently needed.

3. Discovery of Bedaquiline

Bedaquiline (TMC207) was discovered by Janssen scientists, ending a 40-year drought of new TB drugs. Approved in 2012 through accelerated regulatory pathways, it represented a major breakthrough with a new mechanism and no cross-resistance.

4. Novel Mechanism of Action

Bedaquiline works by shutting down the ATP synthase enzyme of M. tuberculosis, cutting off the bacterium’s energy supply. It has:

• Dual-targeting action (c-ring and ε-subunit binding)

• High selectivity for mycobacterial ATP synthase

• Strong sterilizing activity, killing even dormant TB bacteria

5. Pharmacology

Pharmacokinetics:

• Oral drug with better absorption when taken with food

• Long half-life (~5.5 months), which aids intermittent dosing but risks resistance if treatment is interrupted

• Metabolized by CYP3A4 → prone to drug interactions

Dosing:

• 400 mg daily × 2 weeks (loading)

• 200 mg three times weekly × 22 weeks (maintenance)

6. Clinical Efficacy

Phase II trials (C208 & C209) proved strong efficacy:

• Faster sputum culture conversion (83 vs 125 days)

• Higher conversion at 24 weeks (~79% vs ~58%)

• Good outcomes even in pre-XDR and XDR-TB

• Became the basis for global guideline adoption

7. Safety Profile

Key concerns include:

• QT interval prolongation (black box warning)

• Early trial mortality imbalance (later found not drug-related)

• Hepatotoxicity, requiring monthly monitoring
  Common side effects: nausea, joint pain, headache.

8. Regulatory and Global Policy Integration

• FDA accelerated approval (2012) → full approval in 2024

• WHO guidelines evolved from cautious (2013) to strongly supportive (2018 onward)

• Now a core drug (Group A) in MDR-TB therapy

• Approved for children of all ages with pediatric formulations

9. Paradigm Shift to All-Oral, Shorter Regimens

Bedaquiline replaced toxic injectables and enabled modern regimens:

BPaL: Bedaquiline + Pretomanid + Linezolid
BPaLM: BPaL + Moxifloxacin
These new regimens:

• Are 6 months long

• Are all-oral

• Show ~90% success, far better than old 18–24-month injectable regimens

10. Ongoing Challenges

Future priorities include:

• Monitoring emerging bedaquiline resistance

• Ensuring global access and affordability

• Optimizing combinations and dosing

• Developing next-generation ATP synthase inhibitors

Conclusion

Bedaquiline represents a true and undeniable pharmacological breakthrough in the global fight againsttuberculosis.Its introductionendedafour-decade-longperiod of therapeuticstagnation and fundamentally reshaped the standard of care for the most dangerous and difficult-to-treat forms of the disease.Through its novel mechanism of action—the specific inhibition of mycobacterial ATP synthase— bedaquiline provided a powerful new weaponagainst strains ofM. tuberculosis that hadevolved resistance to other drug classes. This efficacy, proven in pivotal clinical trials, enabled the development of all-oral treatment regimens that have transformed patient outcomes. The paradigm has shifted from grueling, two-year-long therapies reliant on toxic injections with a mere 50% chance of success, to a highly effective, six-month, all-oral regimen that cures approximately 90% of patients. This achievement has not only saved countless lives but has also drastically reduced patient suffering.However, the success of this breakthrough is not guaranteed to last. The future utility of bedaquiline hingesonourcollectiveabilitytonavigate thepersistentchallengesofemerging drug resistance.

References

[1] Multidrug-ResistantTuberculosisandExtensivelyDrug-ResistantTuberculosis -PMC- PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC4561400/. [2] Tuberculosis: Extensively drug-resistant tuberculosis (XDR-TB),https://www.who.int/news-room/questions-and-answers/item/tuberculosis-extensively-drug-resistant-tuberculosis-(XDR-TB) [3] AtLongLast: Short,All-OralRegimensforMultidrug-Resistant ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC10135426/ [4] Thecoming-of-ageofbedaquiline:atalewithanopenending-ERSPublications, https://publications. ersnet.org/content /erj/57/6/2100 066 [5] Clinical Overview of Drug-Resistant Tuberculosis Disease - CDC, https://www.cdc.gov/tb/hcp/clinical-overview/drug-resistant-tuberculosis-disease.html [6] Full article: Bedaquiline as part of combination therapy in adults with ..., https://www.tandfonline.com/doi/full/10.1080/17512433.2016.1200462 [7] Bedaquiline |Working Group for New TB Drugs, https://www.newtbdrugs.org/pipeline/compound/bedaquiline-0. [8] Bedaquiline in multidrug-resistant pulmonary tuberculosis GENESIS ..., https://www.elsevier.es/es-revista-farmacia-hospitalaria-121-articulo-bedaquiline-in-multidrug-resistant-pulmonary-tuberculosis-S1130634323006426 [9] (PDF) Bedaquiline: what might the future hold? - ResearchGate, https://www.researchgate.net/publication/382677683_Bedaquiline_what_might_the_future_hold [10] The use of bedaquiline in the treatment of multidrug-resistant ..., https://www.who.int/publications/i/item/9789241505482 [11] Bedaquiline: First FDA-approved tuberculosis drug in 40 years - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3678673/ 12 [12] Bedaquiline -Wikipedia, https://en.wikipedia.org/wiki/Bedaquiline [13] (PDF) Bedaquiline for the treatment of drug-resistant tuberculosis - ResearchGate, https://www.researchgate.net/publication/274011341_Bedaquiline_for_the_treatment_of_drug-resistant_tuberculosis [14] Sirturo | European Medicines Agency (EMA), https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo [15] Re-Understanding the Mechanisms of Action of the Anti ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6963887/ [16] Adjunctive Bedaquiline and Multidrug-Resistant Tuberculosis - NEJM Journal Watch, https://www.jwatch.org/na35363/2014/08/20/adjunctive-bedaquiline-and-multidrug-resistant [17] Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3793534/ [18] Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis, https://publications.ersnet.org/content/erj/47/2/564 [19] Johnson & Johnson Receives Approval from U.S. FDA and European Commission for SIRTURO® (bedaquiline), https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-approval-from-u-s-fda-and-european-commission-for-sirturo-bedaquiline [20] Incidence of QT interval prolongation in patients receiving bedaquiline for drug-resistant tuberculosis in Sub-Saharan Africa: a protocol for systematic review and meta-analysis | BMJ Open, https://bmjopen.bmj.com/content/15/7/e096709 [21] Cardiac safety of bedaquiline: a systematic andcriticalanalysisoftheevidence,https://publications.ersnet.org/content/erj/50/5/170146222. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence - ERS Publications, https://publications.ersnet.org/content/erj/47/2/394 [22] (PDF) Bedaquiline: A review of human pharmacokinetics and drug-drug interactions, https://www.researchgate.net/publication/262610278_Bedaquiline_A_review_of_human_pharmacokinetics_and_drug-drug_interactions [23] QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study - ResearchGate, https://www.researchgate.net/publication/353632874_QT_Interval_Prolongation_in_People_Tre ated_With_Bedaquiline_for_Drug-Resistant_Tuberculosis_Under_Programmatic_Conditions_A_Retrospective_Cohort_Study25.SIRTURO®(bedaquiline)DevelopmentandLaunch -AMR Industry Alliance, https://www.amrindustryalliance.org/case-study/sirturo-bedaquiline- development-launch/ 26. [24] FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of CombinationTherapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis, https://www.jnj.com/media-center/press-releases/fda-grants-accelerated-approval-for-sirturo-be daquiline-as-part-of-combination-therapy-to-treat-adults-with-pulmonary-multi-drug-resistant-tub erculosis 27. U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis, [25] https://www.jnj.com/media-center/press-releases/u-s-fda-approves-new-pediatric-formulation- ofsirturoo-bedaquiline-as-part-of-combination-therapy-to-treat-children-with-pulmonary-multidrug-r esistant-tuberculosis [26] Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis, https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6209a1.htm [27] Sirturo (bedaquiline)FDAApprovalHistory -Drugs.com,https://www.drugs.com/history/sirturo.html [28] WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis - IRIS Home, https://iris.who.int/bitstream/handle/10665/258941/WHO-HTM-TB-2017.20-eng.pdf [29] Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults | Working Group for New TB Drugs, [30] https://www.newtbdrugs.org/news/sirturo-bedaquiline-approved-conditional-use-european-union-treat-mdr-tb-adults [31] Human medicinesEuropeanpublicassessmentreport(EPAR):Sirturo, bedaquiline, Date of authorisation: 05/03/2014, Revision: 22, Status, https://efim.org/node/141494 [32] Europe approves bedaquiline for MDR-TB, https://www.stoptb.org/news/europe-approves-bedaquiline-mdr-tb 34. Bedaquiline | Treatment Action Group, [33] https://www.treatmentactiongroup.org/wp-content/uploads/2013/03/BDQ_guide_10_5_18.pdf [34] WHO Interim policy recommendations - The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK154121/ [35] New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China, https://pmc.ncbi.nlm.nih.gov/articles/PMC11878549/ [36] Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid? - ERS Publications, https://publications.ersnet.org/content/erj/51/3/170248038.Tuberculosis - WHO/ World Health Organisation.[Jun;2022];https://www.who.int/news-room/fact-sheets/detail/tuberculosis2021. [37] Globaltuberculosis report2021 -WHO.[ Jun;2022];https://www.who.int/publications-detail- redirect/9789240037021 2021. [38] TBIndiaReport2021:MinistryofHealthandFamilyWelfare.[Jun;2022];https://tbcindia.gov.in/showfile.php2021. [39] GuidelinesforProgrammaticManagementofDrugResistantTuberculosisinIndia.[Jul; 2022 ];https://tbcindia.gov.in/showfile.php?lid=3625 2021. [40] Therolloutofa TBcuring miracledrug-Bedaquiline.[Jun;2022];https://indianexpress.com/article/explained/tuberculosis-bedaquiline-new... 2016. 43.Bedaquiline:anoveldrugto combat multipledrug-resistant tuberculosis. GoelD.J Pharmacol Pharmacother. 2014;5:76–78. - PMC - PubMed. [41] Bedaquiline:firstFDA-approved tuberculosisdrug in40 years. Mahajan R. IntJApplBasic Med Res. 2013;3:1–2. - PMC - PubMed. [42] GuidelinesforUseofBedaquilineinRNTCPPart1.[Jun;2022];https://tbcindia.gov.in/showfile.php2016. [43] TMC207: thefirst compoundof anewclassof potent anti-tuberculosisdrugs. MatteelliA, Carvalho AC, Dooley KE, Kritski A. Future Microbiol. 2010;5:849–858. - PMC - PubMed. [44] Bedaquiline-WHOCC-ATC/DDDIndex. [Jun; 2022];https://www.whocc.no/atc_ddd_index/2021. [45] Pharmacodynamicsandbactericidalactivityofbedaquilineinpulmonarytuberculosis.Lyons MA. Antimicrob Agents Chemother. 2022;66:0. - PMC - PubMed. [46] Conformationalanalysisofr207910,anewdrug candidateforthetreatmentoftuberculosis, by a combined NMR and molecular modeling approach. Gaurrand S, Desjardins S, Meyer C, Bonnet P, Argoullon JM, Oulyadi H, Guillemont J. Chem Biol Drug Des. 2006;68:77–84. - PubMed. [47] Diarylquinolines target subunit c of mycobacterial ATP synthase. Koul A, Dendouga N, VergauwenK,etal.https://www.infona.pl/resource/bwmeta1.element.elsevier-1d35ec9c-a6b1-34 NatChemBiol.2007;3:323–324.-PubMed. [48] Absolute configurationand structuralfeaturesof R2071910,a novelanti-tuberculosisagent. Petit S, Coquerel G, Meyer C, Guillemont J. J Mol Struct. 2007;837:252–256.. [49] Bedaquiline -ThefirstATPsynthaseinhibitoragainstmultidrugresistanttuberculosis. Lakshmanan M, Xavier AS. J Young Pharm. 2013;5:112–115. - PMC - PubMed. [50] Selectivityof TMC207 towardsmycobacterialATP synthasecompared with thattowardsthe eukaryotichomologue. HaagsmaAC,Abdillahi-IbrahimR,WagnerMJ, etal.AntimicrobAgents Chemother. 2008;53:1290–1292. - PMC - PubMed. [51] Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. HaagsmaAC,Podasca I, KoulA,Andries K, Guillemont J,LillH,Bald D.PLoSOne. 2011;6:0. - PMC - PubMed. [52] Adiarylquinolinedrug activeontheATPsynthaseof Mycobacteriumtuberculosis.AndriesK, Verhasselt P, Guillemont J, et al. Science. 2005;307:223–227. - PubMed. [53] In vitroantimycobacterialspectrumofadiarylquinolineATPsynthase inhibitor.HuitricE, Verhasselt P, Andries K, Hoffner SE. Antimicrob Agents Chemother. 2007;51:4202–4204. - PMC - PubMed. [54] GeneticbasisfornaturalandacquiredresistancetothediarylquinolineR207910in mycobacteria. Petrella S, Cambau E, Chauffour A, AndriesK, Jarlier V, SougakoffW. Antimicrob Agents Chemother. 2006;50:2853–2856. - PMC - PubMed. [55] New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Segala E, Sougakoff W, Nevejans-Chauffour A, JarlierV, Petrella S. Antimicrob Agents Chemother. 2012;56:2326– 2334. - PMC - PubMed. [56] Acquiredresistanceof Mycobacteriumtuberculosistobedaquiline.AndriesK,VillellasC, Coeck N, et al. PLoS One. 2014;9:0. - PMC - PubMed. [57] Emergenceofbedaquiline resistanceina hightuberculosisburden country.ChesovE, Chesov D, Maurer FP, et al. Eur Respir J. 2022;59:2100621. - PMC - PubMed. [58] Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Field SK. Ther Adv Chronic Dis. 2015;6:170–184. - PMC - PubMed. 62.Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. van Heeswijk RP, Dannemann B, Hoetelmans RM. J Antimicrob Chemother. 2014;69:2310–2318. - PubMed. [59] Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. Antimicrob Agents Chemother. 2012;56:1444–1451. - PMC - PubMed. [60] Bedaquiline:anewdrug approvedfortreatmentofmultidrug-resistanttuberculosis. Deoghare S. Indian J Pharmacol. 2013;45:536–537. - PMC - PubMed. [61] Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug- resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Diacon AH, Donald PR, Pym A, et al.Antimicrob Agents Chemother. 2012;56:3271– 3276. - PMC - PubMed. [62] Bedaquiline:anoveldiarylquinolineformultidrug-resistanttuberculosis.ChahineEB, Karaoui LR, Mansour H. Ann Pharmacother. 2014;48:107–115. - PubMed. [63] Bedaquiline:anovelantituberculardrugformultidrug-resistanttuberculosis.Nagabushan H, Roopadevi HS. J Postgrad Med. 2014;60:300–302. - PubMed. [64] A reviewof theevidenceforusing bedaquiline(TMC207)to treatmulti-drug resistant tuberculosis. Fox GJ, Menzies D. Infect Dis Ther. 2013;2:123–144. - PMC - PubMed. [65] ThediarylquinolineTMC207formultidrug-resistanttuberculosis.DiaconAH,PymA, Grobusch M, et al. N Engl J Med. 2009;360:2397–2405. - PubMed. [66] Reportof theGuideline DevelopmentGroup Meetingonthe useof bedaquilinein the treatment of multidrug-resistant tuberculosis A review of available evidence. [ Jun; 2022];https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122575/2016. [67] Multidrug-resistanttuberculosisandcultureconversionwithbedaquiline.DiaconAH,PymA, Grobusch MP, et al. N Engl J Med. 2014;371:723–732. - PubMed. [68] Long-termbedaquiline-relatedtreatmentoutcomesinpatientswithextensivelydrug-resistant tuberculosis from South Africa. Olayanju O, Limberis J, Esmail A, et al. Eur Respir J.2018;51:1800544.-PubMed. [69] Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.Wang MG,WuSQ, HeJQ.BMC Infect Dis.2021;21:970. -PMC - PubMed. 74.Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Ahmad N, Ahuja SD, Akkerman OW, et al. Lancet.2018;392:821–834.-PMC-PubMed. [70] Bedaquiline-containingregimensandmultidrug-resistanttuberculosis:asystematicreview and meta-analysis. Hatami H, Sotgiu G, Bostanghadiri N, et al. J Bras Pneumol. 2022;48:0. - PMC - PubMed. [71] Evaluationofpharmacokineticpharmacodynamicrelationshipsandselectionofdrug combinations for tuberculosis. Muliaditan M, Della Pasqua O. Br J Clin Pharmacol.2021;87:140–151.-PubMed. [72] Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosisdruguse:an individualpatientdata meta-analysis.BissonGP,BastosM,Campbell JR, et al. Lancet. 2020;396:402–411. - PMC - PubMed. [73] Assessment of epidemiological and genetic characteristics and clinical outcomes of resistancetobedaquiline in patientstreatedforrifampicin-resistant tuberculosis: across- sectionaland longitudinalstudy.IsmailNA, OmarSV, MoultrieH,etal.LancetInfect Dis. 2022;22:496–506. - PubMed. [74] Earlyoutcomeandsafetyof bedaquiline-containingregimensfortreatment of MDR-and XDR-TB in China: a multicentre study. Gao M, Gao J, Xie L, et al. Clin Microbiol Infect.2021;27:597–602.–PubMed.

Copyright

Copyright © 2025 Md. Arif Raza, Prashant Kumar, Prashant Raj, Dr. Nakul Gupta, Mr. Sudhir Arora. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.